Steven Feldman to Thalidomide
This is a "connection" page, showing publications Steven Feldman has written about Thalidomide.
Connection Strength
2.655
-
Feldman SR, Pelletier CL, Wilson KL, Mehta RK, Brouillette MA, Smith D, Bonafede MM. Treatment patterns and costs among biologic-naive patients initiating apremilast or biologics for psoriatic arthritis. J Comp Eff Res. 2019 07; 8(9):699-709.
Score: 0.659
-
Feldman SR, Pelletier CL, Wilson KL, Mehta RK, Brouillette MA, Smith D, Bonafede MM. Real-world US healthcare costs of psoriasis for biologic-naive patients initiating apremilast or biologics. J Comp Eff Res. 2019 01; 8(1):45-54.
Score: 0.636
-
Moustafa F, Feldman SR. A review of phosphodiesterase-inhibition and the potential role for phosphodiesterase 4-inhibitors in clinical dermatology. Dermatol Online J. 2014 May 16; 20(5):22608.
Score: 0.466
-
Shutty B, West C, Pellerin M, Feldman S. Apremilast as a treatment for psoriasis. Expert Opin Pharmacother. 2012 Aug; 13(12):1761-70.
Score: 0.409
-
Feldman SR, Zhang J, Martinez DJ, Lopez-Gonzalez L, Marchlewicz EH, Shrady G, Mendelsohn AM, Zhao Y. Real-world treatment patterns and healthcare costs of biologics and apremilast among patients with moderate-to-severe plaque psoriasis by metabolic condition status. J Dermatolog Treat. 2021 Mar; 32(2):203-211.
Score: 0.171
-
Kolli SS, Kepley AL, Cline A, Feldman SR. A safety review of recent advancements in the treatment of psoriasis: analysis of clinical trial safety data. Expert Opin Drug Saf. 2019 06; 18(6):523-536.
Score: 0.165
-
Cline A, Cardwell LA, Feldman SR. Advances in treating psoriasis in the elderly with small molecule inhibitors. Expert Opin Pharmacother. 2017 Dec; 18(18):1965-1973.
Score: 0.149